Misoprostol Composition
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the use of misoprostol for the induction of labour in a pregnant female, and in particular to the use of a sustained delivery device or insert containing substantially 200 μg misoprostol for intravaginal use. The use encompasses methods of therapy as well as compositions for use in such methods.
-
Citations
48 Claims
-
1-8. -8. (canceled)
-
9. A method of achieving one or more of:
-
(i) a reduction in the incidence of category II foetal heart rate pattern; (ii) a reduction in incidences of intrapartum resuscitation; (iii) reduced use of tocolytics; (iv) a reduced incidence of meconium in amniotic fluid; (v) a reduced requirement for a caesarean delivery during first hospitalisation; (vi) a reduced requirement for instrumented vaginal delivery during first hospitalisation; and (vii) a reduced incidence of postpartum haemorrhage. in a female induced for labour due to pre-eclampsia, said method comprising administering intravaginally to the female an insert comprising a cross-linked polyurethane reaction product of a polyethylene glycol, a triol and a diisocyanate, the insert containing 200 μ
g misoprostol;(i), (ii), (iii), (iv), (v), (vi), and (vii) being reduced in comparison to the administration of said insert containing 10 mg dinoprostone. - View Dependent Claims (39, 40, 41, 42, 43, 44, 45, 46, 47)
-
-
10-38. -38. (canceled)
-
48. A method of achieving:
-
(i) a reduction in the incidence of category II foetal heart rate pattern; (ii) a reduction in incidences of intrapartum resuscitation; (iii) reduced use of tocolytics; (iv) a reduced incidence of meconium in amniotic fluid; (v) a reduced requirement for a caesarean delivery during first hospitalisation; (vi) a reduced requirement for instrumented vaginal delivery during first hospitalisation; and (vii) a reduced incidence of postpartum haemorrhage. in a female induced for labour due to pre-eclampsia, said method comprising administering intravaginally to the female an insert comprising a cross-linked polyurethane reaction product of a polyethylene glycol, a triol and a diisocyanate, the insert containing 200 μ
g misoprostol;(i), (ii), (iii), (iv), (v), (vi), and (vii) being reduced in comparison to the administration of said insert containing 10 mg dinoprostone.
-
Specification